SUPN

Supernus Pharmaceuticals, Inc. | Cotação de Ações

Última atualização24/12/2024, 15:00:00

PreçoUS$ 35,60

Variação (dia)US$ 0,01 (0.03%)▲

Min. 52 SemanasUS$ 25,53

Máx. 52 SemanasUS$ 39,37

Capitalização de mercado--

Endereço: 9715 Key West Avenue, Rockville, MD, 20850

Telefone: 301 838 2500

Funcionários: 652

Supernus Pharmaceuticals, Inc.SUPN

US$ 35,60

+ 0,010,028%

24/12/2024 15:00:00

1D 7D 1M 3M 1A Tudo

Visão geral da empresa

Preço atualUS$ 35,60

Valor de mercado--

AberturaUS$ 36,08

Preço máximoUS$ 35,63

Preço mínimoUS$ 34,99

VolumeUS$ 125 mil

Fechamento anteriorUS$ 35,59

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

Ações relacionadas

Pacira BioSciences, Inc.

PCRX ▲0.27% | US$ 19,47

Innoviva, Inc.

INVA ▼0.01% | US$ 17,78

Corcept Therapeutics Incorporated

CORT ▲1.27% | US$ 52,17

Ironwood Pharmaceuticals, Inc.

IRWD ▲0.02% | US$ 4,61

Eagle Pharmaceuticals, Inc.

EGRX ▼0.03% | US$ 0,52

Encontre respostas para suas dúvidas sobre investimentos em nossa seção de Perguntas Frequentes (FAQ)

Acesse a seção de Perguntas Frequentes da brapi para esclarecer dúvidas sobre investimentos. Nossa FAQ fornece informações concisas, abordando tópicos relevantes para investidores, contribuindo para uma compreensão mais clara do mercado financeiro.

Assine nossa newsletter para receber atualizações gratuitas por e-mail

Mantenha-se informado assinando nossa newsletter. Receba atualizações gratuitas por e-mail, incluindo rendimentos, novidades do mercado e insights valiosos. Estamos comprometidos em fornecer informações relevantes diretamente à sua caixa de entrada.

Explore os ativos do mercado financeiro em tempo real com a nossa API

A API da brapi proporciona uma visão dos ativos do mercado financeiro. Com gráficos interativos e dados atualizados, oferecemos uma análise abrangente das tendências do mercado. Os desenvolvedores podem personalizar os módulos, configurar o range de tempo e escolher todos os dados necessários para decisões informadas.